December 10, 2018 8:14am

After last week’s volatility for investors; we’re in for more “drifting”

News: Voyager Therapeutics (VYGR) dosed the first patient in RESTORE-1, a P2, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of VY-AADC for the treatment of Parkinson’s disease in patients with motor fluctuations that are refractory to medical management.


I answer one question, in which company should investors put, keep and commit their money!

In compiling my indication signals, specific knowledge of the sector and its practices as to lessons learned.  It’s important for investors to identify and determine which indication is actually performance based.

Members only. Please login.